Related Experiment Video

Updated: Jul 14, 2026

Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

Mitochondrial Dynamics as Determinants of Cancer Drug Resistance: A Systematic Review

Swaroop Kumar Pandey1, Ayush Kulshreshtha1, Anuja Mishra1

  • 1Department of Biotechnology, Institute of Applied Science & Humanities, GLA University, Mathura - 281406, U.P., India.

Current Cancer Drug Targets
|July 13, 2026
PubMed
Abstract

Insights

Mitochondrial dynamics, crucial for cell function, become dysregulated in cancer, promoting drug resistance. Targeting proteins like DRP1 and OPA1 offers new strategies to enhance cancer therapies by disrupting cancer cell metabolism.

Area of Science:

  • Mitochondrial dynamics and cancer biology.
  • Cellular organelle homeostasis and function.

Background:

  • Mitochondria are essential for cellular function through continuous fission and fusion.
  • Dysregulation of mitochondrial dynamics contributes to cancer progression, drug resistance, and metastasis.

Purpose of the Study:

  • To review the role of mitochondrial dynamics in cancer drug resistance.
  • To discuss therapeutic strategies targeting mitochondrial dysfunction in cancer.

Main Methods:

  • Synthesized recent research on mitochondrial dynamics in cancer.
  • Focused on key proteins: DRP1, MFN1, MFN2, and OPA1.
  • Integrated cellular-level understanding with drug-resistant cancer findings.

Main Results:

  • Dysregulated DRP1, MFN1, MFN2, and OPA1 enable cancer cells to survive treatments.
  • Altered mitochondrial function impacts energy production, ROS management, and apoptosis.
  • Drug-resistant tumors exhibit mitochondrial remodeling, with mitophagy enhancing cell survival.

Conclusions:

  • Mitochondrial adaptations allow cancer cells to evade therapies.
  • Targeting DRP1, OPA1, and other proteins offers therapeutic potential.
  • Modulating mitochondrial dynamics can disrupt cancer metabolism and overcome drug resistance.
Keywords:
MitochondriaROS.apoptosiscancer drugsfissionfusion

More Related Videos

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity07:58

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity

Published on: May 12, 2020

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Mitochondrial Membranes01:45

Mitochondrial Membranes

A single mitochondrion is a bean-shaped organelle enclosed by a double-membrane system. The outer membrane of mitochondria is smooth and contains many porins - the integral membrane transporters. Porins enable free diffusion of ions and small uncharged molecules through the outer mitochondrial membrane but limit the transport of molecules larger than 5000 Daltons. Further, the outer mitochondrial membrane forms a unique structure called membrane contact sites with other subcellular organelles,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...